Navigation Links
Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
Date:6/22/2011

CAMBRIDGE, England, June 21, 2011 /PRNewswire/ --


 

Crescendo Biologics Limited (Crescendo) today announces the appointment of Matthew Roe as Chief Business Officer. Matthew joins Crescendo from Genzyme Corporation where he was Senior Director, Business Development & Licensing.

During a 23-year career at Genzyme, Matthew was active in licensing, alliance management, acquisition, divestment, and sales and marketing, and saw the corporation develop from an entrepreneurial start-up to a leading multi-national biotechnology company. He negotiated and managed multiple agreements for drug delivery technologies in the USA, Europe and Japan and was also a core team member on the divestment of Genzyme's Pharmaceuticals business.

Mike Romanos, CEO of Crescendo said: "Matthew's track record in business development speaks for itself. He has an exceptional depth of experience in business strategy and in implementing agreements across multiple territories. I look forward to working with him as we build on the significant advances we have made at Crescendo and position the Company to deliver real value from its world class, proprietary technology platforms."

Matthew Roe, CBO of Crescendo said: "The monoclonal antibody market is rapidly growing and continues to be a major focus for the pharma industry. Companies are searching for new platforms and approaches, particularly in the area of antibody fragments. Crescendo's technology platform, IP and insight create a strong foundation from which to make a significant impact in the field and I am delighted to be joining the Company's management team as it seeks to grow to become a leader in next-generation antibody therapeutics."

About Crescendo Biologics Ltd

Crescendo Biologics will apply highly innovative antibody fragment technologies to the development of new targeted therapeutics. The Crescendo transgenic mouse platform under development has the potential to rapidly
'/>"/>

SOURCE Crescendo Biologics Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Crescendo Biologics Announces First Triple Knockout Mouse
2. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
3. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
4. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
5. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
6. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market
7. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
8. New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma
9. Reportlinker Adds Biotechnology Industry 2010 Yearbook - Top Biologics, Biosimilars, Licensing and Financing, Mergers and Acquisitions
10. Dendreon Submits Post-Approval Supplement to the PROVENGE Biologics License Application for New Jersey Manufacturing Facility
11. Reportlinker Adds Immunogenicity to Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
(Date:3/3/2015)... , March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: ... proprietary technologies and products for advanced microarray diagnostics, ... CA, CFE  to its Management team. In his ... in its transition from a development stage to ... to advance the Company,s capital market strategy and ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... Md. , March 3, 2015  RegeneRx Biopharmaceuticals, ... editorial in the scientific journal, Expert Opinion on ... his colleague, Dr. Zhenggang Zhang , at the ... reported that Thymosin beta 4 (TB4) has the ... remodeling 24 hours or more post-injury, leading to neurological ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... Feature Public and Private Life Science Companies from ... ... for the,Southern California life science community, is proud to announce that ... Diego,Marriott Del Mar from Oct. 31-Nov. 2, 2007. Featuring almost ...
... Tissue Ligating ... ... surgical device company, has been named a 2007 Innovator of the,Year ... for its newest Tissue Ligating Shears, the TLS3,which uses the Company,s ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2BIOCOM Announces Second Annual Investor Conference 2Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 2
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015  Businesses have ... Data protection company Tharon Rankins Enterprises has announced ... provides an ultra-safe way for businesses to protect ... financial transactions. Beconux is a ... Rankins Enterprises. Functioning similarly to an ATM machine, ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... PASADENA, Calif.A California Institute of Technology (Caltech)-led ... first proof that a targeted nanoparticleused as an ... bloodstreamcan traffic into tumors, deliver double-stranded small interfering ... gene using a mechanism known as RNA interference ...
... A potential new energy source so controversial that people once ... by the mainstream scientific community. That,s the conclusion of the ... topic "cold fusion" being held here for the ... National Meeting of the American Chemical Society (ACS). "Years ...
... , , Michael M. Graham, Ph.D., M.D., president, ... chair, SNM Medical Isotope Task Force, Jeffrey P. Norenberg, ... member, SNM Medical Isotope Task Force, WHEN:,Immediately ... over a two-week period when cancer, heart and brain ...
Cached Biology News:Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4
... were designed for full-length gene cloning and ... identify the desired cDNA clone. The first ... "Master Plate," where each well contains plasmid ... positive well(s) by gel electrophoresis of the ...
... CEQ 8800 Genetic Analysis System, which processes ... This automated system adds a higher level of ... CEQ 8800, part of Beckman Coulters new GenomeLab ... link with the Biomek series liquid handers, for ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
... cDNA Library Panels were designed for full-length ... of PCRs to identify the desired cDNA ... in a 96-well "Master Plate," where each ... Having identified the positive well(s) by gel ...
Biology Products: